NYLIM
KNSA icon

New York Life Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

New York Life Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,856
Closed -$352K – 1113
2024
Q1 		$352K Buy
+17,856
New +$349K ﹤0.01% 1282

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York Life Investment Management's KNSA Position: Q2 2024 in Review

New York Life Investment Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2024, closing a stake of 17,856 shares — an estimated $352K sold.

New York Life Investment Management first reported a position in KNSA in Q1 2024 and held it in 1 quarter. The position peaked at $352K in Q1 2024. 132 funds tracked by Wall St. Rank hold KNSA as of Q2 2024.

  • New York Life Investment Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 17,856 Kiniksa Pharmaceuticals shares in Q2 2024, an estimated $352K.
  • New York Life Investment Management first reported a position in Kiniksa Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • New York Life Investment Management's Kiniksa Pharmaceuticals position peaked at $352K in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.